​

First-to-market and longest-running polynucleotide distributor, Amedica, introduces Ameela. Over the past 10 years, Amedica has been fortunate enough to be at the forefront of injectable technology, and has launched and established a global market for injectable polynucleotide skin treatments.

​

With an influx of brands added to the polynucleotide mix - and an ever-growing demand for these treatments - the decision was made to rebrand Nucleadyn to Ameela. This was due to the previous confusion between Nucleadyn and another brand, as well as to differentiate from the crowd. Ameela has an unrivalled quality assurance that we can offer confidently, due to our clinical data and portfolio of case studies. Nothing else aside from marketing and name associations has changed, with all product formulations and indications staying the same.
 

All products going forward will be Ameela branded, and all existing and new clients will receive the updated digital marketing material. Please do not hesitate to get in touch with any questions. 

​

​

​

​